Collaboration and Licensing Revenue (Tables)

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2022 and 2021.

	Three Months Ended   March 31,
	2022		2021
Castle Creek Biosciences, Inc.	$	—	$	59
Other	—		7
Total (1)	$	—	$	66

(1)Collaboration and licensing revenues include the recognition of $0 and $66 for the three months ended March 31, 2022 and 2021, respectively, associated with upfront and milestone payments which were previously deferred.

Summary of Deferred Revenue

Deferred revenue consisted of the following:

	March 31, 2022		December 31, 2021
Collaboration and licensing agreements	$	23,023	$	23,023
Prepaid product and service revenues	2,511		4,229
Other	158		213
Total	$	25,692	$	27,465
Current portion of deferred revenue	$	2,669	$	4,442
Long-term portion of deferred revenue	23,023		23,023
Total	$	25,692	$	27,465

Summary of Deferred Revenue by Collaborator